Medicines List

Select category
  • Description

    Dilatrend contains the active substance carvedilol, which affects the α- and β-adrenergic receptors. It was found that carvedilol has organ-protective and powerful antioxidant effect. It also reduces peripheral vascular resistance.

    Indications

    Dilatrend is indicated for:

    Chronic Heart Failure
    Dilarend is indicated for the treatment of all patients with stable and symptomatic mild, moderate and severe chronic heart failure of ischaemic or non-ischaemic aetiology in combination with standard therapy (including ACE inhibitors and diuretics with or without digitalis).

    Hypertension
    Dilatrend is indicated for the treatment of essential hypertension. It can be used alone or in combination with other anti-hypertensive agents (e.g. calcium channel blockers, diuretics).

    Angina Pectoris
    Dilatrend is indicated for the prophylactic treatment of stable angina.

    Subject to medical prescription.

    Concentration and pharmaceutical form: 6.25 mg, 12.5 mg, 25 mg tablets

    Patient information leaflet

  • Description

    Lidocaine – Tchaikapharma contains the active substance lidocaine hydrochloride, which belongs to a group to medicines called local anesthetics. He belongs to the group of so-called antiarrhythmic drugs.

    Indications

    Lidocaine – Tchaikapharma is used for:
    – local anesthesia (anesthesia) during various painful procedures and examinations in surgery, dentistry and others;
    – treatment of severe heart rhythm disorders (ventricular arrhythmias), including after myocardial infarction.

    Subject to medical prescription.

    Concentration and pharmaceutical form: 10 mg/ml solution for injection

    Patient information leaflet

     

  • Description

    Tirofiban-Tchaikapharma belongs to group of medicines called antithrombotic agents. Tirofiban prevents platelets from sticking together and thus forming blood clots, which can reduce blood flow to the heart and cause chest pain and heart attacks.

    Indications

    Tirofiban-Tchaikapharma is indicated for the prevention of adult patients with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes. Patients who are most likely to benefit from Tirofiban-Tchaikapharma treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those who are likely to undergo an early percutaneous coronary intervention (PCI). Tirofiban-Tchaikapharma is also indicated for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI.

    Tirofiban-Tchaikapharma is intended for use with acetylsalicylic acid (ASA) and unfractionated heparin.

    Subject to medical prescription.

    Concentration and pharmaceutical form: 0.25 mg/ml concentrate for solution for infusion

    Patient information leaflet

  • Description

    Cardifriend-Co is a combination of two medicines – ramipril and hydrochlorothiazide.

    Ramipril belongs to a group of medicines called “ACE inhibitors” (Angiotensin Converting Enzyme Inhibitors).

    It works by:
    – decreasing body production of substances that raise blood pressure;
    – making blood vessels relax and widen;
    – making it easier for your heart to pump blood around the

    Hydrochlorothiazide belongs to a group of medicines called “thiazide diuretics” or water tablets. It works by increasing the amount of water (urine) the body produces. This lowers blood pressure.

    Indications

    Cardifriend-Co is indicated for treatment of hypertension. This fixed dose combination is indicated in patients whose blood pressure is not adequately controlled with ramipril alone or hydrochlorothiazide alone.

    Subject to medical prescription.

    Concentration and pharmaceutical form: 5 mg/12.5 mg tablets

    Patient information leaflet